Avalon BioVentures I, LP, 10% Owner at Janux Therapeutics, Inc. (JANX), sold 552,182 shares at $47.00 ($25.9M) on 2024-09-12, disclosed to the SEC on 2024-09-12.
Open-market sale of $25.9M JANX by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $46.13 | 2,193 | $101K | 0.4% |
| 2 | $46.13 | 2,193 | $101K | 0.4% |
| 3 | $46.13 | 11,319 | $522K | 2.0% |
| 4 | $46.13 | 11,319 | $522K | 2.0% |
| 5 | $46.13 | 11,557 | $533K | 2.1% |
| 6 | $46.13 | 11,557 |
| $533K |
| 2.1% |
| 7 | $46.66 | 6,649 | $310K | 1.2% |
| 8 | $46.66 | 35,047 | $1.6M | 6.3% |
| 9 | $46.66 | 34,326 | $1.6M | 6.2% |
| 10 | $46.66 | 34,326 | $1.6M | 6.2% |
| 11 | $46.66 | 35,047 | $1.6M | 6.3% |
| 12 | $46.66 | 6,649 | $310K | 1.2% |
| 13 | $47.00 | 30,613 | $1.4M | 5.6% |
| 14 | $47.00 | 161,356 | $7.6M | 29.3% |
| 15 | $47.00 | 158,031 | $7.4M | 28.7% |
| Total | $46.83 avg | 552,182 | $25.9M | 100% |
| Filing → |